Skip to main content
. Author manuscript; available in PMC: 2024 Nov 1.
Published in final edited form as: J Steroid Biochem Mol Biol. 2023 Sep 15;234:106399. doi: 10.1016/j.jsbmb.2023.106399

Figure 5: Inhibition of the PDGFR/JAK/STAT signaling pathway is cytotoxic in patient-derived organoid models of early stage/grade endometrial cancer.

Figure 5:

PDO models were exposed to the indicated agents for 72 hrs, followed by assessment of cell viability. Drugs concentrations are as follows: 1 μM cediranib; 20 μM ruxolitinib; 1 μM tofacitinib; 0.5 μM napabucasin. Data were normalized to control, which was set at 100% viability. Cases are ordered by PR expression (H-score). * p < 0.05; ** p < 0.01; *** p < 0001; **** p < 0.00001 by one-way ANOVA with a Tukey’s multiple comparisons test.